Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Amunix_Pharmaceuticals
|
| gptkbp:activities |
inhibition of neuronal cell death
|
| gptkbp:appointed_by |
oral medication
|
| gptkbp:approves |
gptkb:2022
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:clinical_trial |
gptkb:Europe
gptkb:North_America gptkb:CENTAUR_trial gptkb:PHOENIX_trial Phase 2/3 |
| gptkbp:collaborations |
academic institutions
clinical research organizations |
| gptkbp:contraindication |
hypersensitivity to components
|
| gptkbp:developed_by |
gptkb:Amylyx_Pharmaceuticals
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:education |
provided by healthcare providers
|
| gptkbp:feedback |
generally positive
|
| gptkbp:formulation |
combination therapy
|
| gptkbp:frequency |
twice daily
|
| https://www.w3.org/2000/01/rdf-schema#label |
AMX-0035
|
| gptkbp:ingredients |
gptkb:sodium_phenylbutyrate
C19 H22 N4 O4 S Taurursodiol |
| gptkbp:interacts_with |
may interact with other medications
|
| gptkbp:invention |
gptkb:Amylyx_Pharmaceuticals
|
| gptkbp:is_effective_against |
improves survival
slows disease progression |
| gptkbp:is_used_for |
treatment of amyotrophic lateral sclerosis
|
| gptkbp:label |
includes dosage instructions
includes contraindications includes side effects includes warnings |
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Amylyx_Pharmaceuticals
|
| gptkbp:market |
September 2022
ongoing studies available in the US available in Canada |
| gptkbp:marketed_as |
brand name Relyvrio
|
| gptkbp:pharmacokinetics |
absorbed in gastrointestinal tract
modulates cellular stress response |
| gptkbp:population |
adults
|
| gptkbp:price |
varies by insurance
|
| gptkbp:provides_information_on |
included in ALS treatment guidelines
|
| gptkbp:publishes |
multiple peer-reviewed articles
clinical trial results published |
| gptkbp:receives_funding_from |
private investments
NIH grants |
| gptkbp:regulatory_compliance |
conditional approval
|
| gptkbp:research_focus |
neuroprotection
metabolic modulation |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:scholarships |
gptkb:stock_market_index
|
| gptkbp:side_effect |
fatigue
nausea abdominal pain decreased appetite diarrhea monitoring required |
| gptkbp:storage |
room temperature
|
| gptkbp:target_audience |
patients with ALS
|